Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset

By / 20/03/2023

Novartis presented new data which underscore the transformational and sustained benefit of Zolgensma®, an essential one-time gene therapy for the treatment of spinal muscular atrophy.